Healthcare Translation Research Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Rejuvenation Res. 2019 Jun;22(3):254-260. doi: 10.1089/rej.2018.2122. Epub 2019 May 6.
Based on experience and the existing limited research literature in biotechnology corporate governance, the authors propose potential attributes of minimum corporate governance standards for biotechnology companies, as a basis for further quantitative and qualitative research. The authors assert that the recent proliferation of biotechnology start-up organizations is substantively changing inter- and intraorganizational cultures throughout the health care sector via a "." Therefore, governance decisions and actions-both positive and negative-that are instituted in start-up biotech companies may set new norms for other start-up biotech companies, the larger (bio)pharmaceutical companies by which they are acquired and the range of health care subsector actors that interact with biotechnology companies. The authors stress the importance of appropriate, proportionate, and consistent biotech corporate governance throughout company lifecycles, not simply to support value inflection or as a response to a crisis. Fail to govern, fail to succeed-for investors and, most importantly, for patients.
基于在生物技术公司治理方面的经验和现有有限的研究文献，作者提出了生物技术公司最低公司治理标准的潜在属性，作为进一步进行定量和定性研究的基础。作者断言，最近生物技术初创组织的大量涌现正在通过“范式转移”实质性地改变整个医疗保健行业内和行业间的文化。因此，初创生物技术公司制定的治理决策和行动——无论是积极的还是消极的——都可能为其他初创生物技术公司、收购它们的大型（生物）制药公司以及与生物技术公司互动的广泛医疗保健子行业参与者设定新的规范。作者强调了在整个公司生命周期中实施适当、相称和一致的生物技术公司治理的重要性，这不仅仅是为了支持价值拐点，也不仅仅是对危机的回应。如果不治理，就无法成功——无论是对投资者，还是对患者来说，最重要的都是如此。
